The Hospital-University research in Health (RHU), funded by the Programme Investissements d'Avenir, aims to boost the transfer of scientific innovations to healthcare practice by promoting the establishment of a continuum between fundamental and clinical research. By involving the academic, hospital and corporate sectors, RHU projects aim to improve patient care, strengthen understanding of diseases and promote the emergence of more effective and tolerated treatments.

Aix-Marseille Université coordinates 3 RHU projects:

- The EPINOV and PIONeeR projects are among the 10 RHU projects selected in France in 2017 and have a budget of €5.8M and €8.5M respectively, for a period of 5 years.
- The INNOV-CKD project is one of the 15 laureates selected in 2019 and has a budget of €5.08M, for 5 years.


Coordinated by Professor Fabrice Bartoloméi, this project focuses on the use of large-scale modelling of epileptogenic networks to guide surgical strategies. It consists of a multicenter trial involving 11 epilepsy surgery centers in France, using neuroinformatic brain simulation technology developed by the researchers. This project involves five partners : AMU, INSERM, AP-HM, Hospices civils de Lyon and Dassault Systèmes.


This project, led by Professor Fabrice Barlési, consists in evaluating the obstacles in immunotherapy treatments for lung cancer. Based on a consortium of 9 partners (Aix-Marseille Université, INSERM, AP-HM, Institut Paoli Calmette, Centre Léon Bérard, and the companies AstraZeneca, Innate-Pharma, HalioDX, Imcheck Therapeutics), this project aims to :

  • Decipher the complex mechanisms of resistance to inhibitory antibodies at the immune control point;
  • Develop new therapeutic combinations;
  • Expand the range of immuno-modulating drugs for lung cancer;
  • Provide new diagnostic and therapeutic options for these patients.


Coordinated by Professor Laurent Bonello, of the Cardiology Department of the North Hospital (AP-HM), this project aims to develop innovative and automated methods that can be used in clinical practice to predict the individual risk of coronary complications in patients with chronic renal disease. Cause of myocardial infarction, the acute coronary syndrome affects 100,000 people in France and 800,000 in the United States each year. In 20 to 40% of cases, it concerns patients with chronic renal failure. This project brings together recognized experts in vascular biology, nephrology and cardiology and leading manufacturers in the production of innovative hemostasis tests.

Contact information

Project officer, Tech Transfer
under recruitment

Contact Céline Bréal

Tel: 04 91 39 39 65 51 - email: celine.breal@univ-amu.fr